ArticleHeliyon2024

PMEL is a predictive biomarker for mTORC1 inhibitor treatment of renal angiomyolipoma in tuberous sclerosis complex patients.

Dongxu Qiu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.